Dr Michael Chao, MBBS, FRANZCR. Michael is a radiation oncologist specialising in breast, lower gastrointestinal and prostate cancers. He has over 12 years of experience as a radiation oncologist.
His particular area of expertise is in Prostate Brachytherapy, which includes both Iodine-125 low dose rate (LDR) permanent seed implants and Iridium-192 high dose rate (HDR) temporary implants for prostate cancers. He has directed the development of Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT) and ARC Radiation Therapy at GenesisCare. He consults at the Ringwood and Frankston GenesisCare Radiation Oncology Centres. He has admitting rights to the Epworth Freemason’s Hospital and Ringwood Private Hospital. He is also an honorary radiation oncologist at the Royal Melbourne and Maroondah Hospital.
Michael completed his MBBS at Monash University in 1991 graduating with honours. He won the Jean C. Tolhurst Prize in Medicine. He then completed 6 years of postgraduate training at the Repatriation Hospital and Peter MacCallum Cancer Centre as a resident and registrar specialising in Radiation Oncology. He received his Fellowship of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 1999. This was followed by two years as a research fellow at the DNA Research Laboratory at the Peter MacCallum Cancer Centre. He was both an NHMRC Scholar and Sir Edward ‘Weary’ Dunlop Research Fellow.
He commenced as a consultant radiation oncologist in 2000 joining GenesisCare.
Michael is a member of the American Society of Therapeutic Radiology and Oncology, American Society of Clinical Oncology, Australasian Society of Breast Diseases, Australian Gastrointestinal Trials Group, American Brachytherapy Society, Australasian Brachytherapy Group and the Victorian Co-operative Oncology Group as a representative in the Colorectal Cancer Committee. He also represented oncology on the Medical Advisory Committee at Freemason’s Hospital from 2001-2005.
He has presented and published widely on a range of subjects in radiation oncology. He is involved in clinical trials and currently has a number of ongoing studies in prostate and breast cancer. He regularly attends international conferences, and keeps abreast of all latest developments in radiation oncology, particularly in his areas of interest.